Definium Therapeutics Financial Ratios
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
36.90+2.72 (+7.96%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Definium Therapeutics ratio analysis
Return on equity reached -55.3%, meaning Definium Therapeutics generated -0.55 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.12 versus 0.09 the year before, and the current ratio was 6.29. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Definium Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / book | 3.67 | 2.10 | 1.83 | 0.45 | 3.74 | 160.54 |
| Return on equity (ROE) | -55.3% | -45.0% | -122.5% | -37.6% | -61.3% | -44.7% |
| Return on assets (ROA) | -41.8% | -36.0% | -76.9% | -33.4% | -56.7% | -41.6% |
| Debt / equity | 0.12 | 0.09 | 0.18 | — | — | — |
| Current ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 |